Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Eléonora De Martin(Université Paris-Saclay), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ciro Celsa(Department of Health), Astrid Laurent-Bellue(Bicêtre Hospital), Pasquale Lombardi(Università Cattolica del Sacro Cuore), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Aria Torkpour(Imperial College London), Antonio D’Alessio(Hammersmith Hospital)
Cited by 36
Related Papers
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
|JAMA Oncology|2019|582
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
|Journal of Hepatology|2019|205
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
|The Lancet Oncology|2023|184
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease
|Clinical Gastroenterology and Hepatology|2019|152